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Objectives. The purpose of this study was to monitor the effects
of chimeric 7E3 Fab (ReoPro) on leukocyte and platelet activation
and interaction during coronary angioplasty.
Background. Increased expression of CD11b on monocytes and
neutrophils promotes their adhesion to endothelial cells, extracel-
lular matrix and smooth muscle cells. Thrombin-activated plate-
lets adhere via P-selectin to monocytes and neutrophils. These cell
interactions may affect the outcome of coronary angioplasty.
Methods. During coronary angioplasty, venous blood was ob-
tained for flow cytometric detection of leukocyte CD11b; platelet
CD41a, CD61a and CD62P; the percentage of leukocytes with
adherent platelets and the intensity of bound platelet fluores-
cence.
Results. Leukocyte CD11b expression increased after angio-
plasty in control patients (neutrophils 171 6 25 to 255 6 31 mean
fluorescence intensity [MFI, mean 6 SEM], n 5 25, p < 0.0001;
monocytes 200 6 40 to 248 6 36 MFI, n 5 17, p < 0.05) and
decreased in the patients selected to receive chimeric 7E3 Fab
(neutrophils 146 6 30 to 82 6 22 MFI, n 5 25, p < 0.0001;
monocytes 256 6 53 to 160 6 38 MFI, n 5 17, p < 0.05).
Neutrophil CD11b decreased after in vitro incubation of whole
blood with chimeric 7E3 Fab (n 5 5, p 5 0.01), but fMLP-induced
increases in CD11b were not prevented. The CD11b expression
was unchanged and increased with fMLP stimulation after in
vitro incubation of isolated neutrophils with chimeric 7E3 Fab.
Direct-labeled chimeric 7E3 Fab was not detected bound to
neutrophils in whole blood or isolated cells using flow cytometric
techniques. Adhesion of isolated neutrophils to protein-coated
glass was not prevented by in vitro incubation with chimeric 7E3
Fab. Platelet activation increased after angioplasty in control
patients (CD62P 8.9 6 0.8 to 12.3 6 1.2 MFI, n 5 25, p < 0.05;
CD41a 382 6 25 to 454 6 26 MFI, n 5 25, p < 0.05, CD61a 436 6
52 to 529 6 58 MFI, n 5 11, p < 0.05); it did not increase in the
patients selected to receive chimeric 7E3 Fab (CD62P 13.2 6 1.0
to 9.0 6 0.9 MFI, n 5 25, p < 0.05; CD61a 398 6 32 to 410 6 38
MFI, n 5 7, p 5 NS). Leukocytes with adherent platelets tended
to increase in the control group of patients and decrease after the
procedure in patients selected to receive chimeric 7E3 Fab;
individual and procedure-related variability were marked.
Conclusions. Despite standard aspirin and heparin therapy,
leukocyte and platelet activation with platelet adherence to leu-
kocytes occurs after coronary angioplasty. Although chimeric 7E3
Fab does not bind to leukocytes directly, it influences CD11b
expression in whole blood. Modulation of platelet and leukocyte
activation and interaction by chimeric 7E3 Fab may contribute to
an improved outcome after coronary angioplasty.
(J Am Coll Cardiol 1999;33:97–106)
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Coronary angioplasty is a routinely used invasive modality for
the treatment of stable angina, unstable angina and acute
myocardial infarction. While the initial success rate is very
high, long-term and event-free survival has been limited by
restenosis and progression of atherosclerotic disease (1,2).
New devices, in particular the heparin-coated stent with ticlo-
pidine, have shown improved event-free survival in patients
with stable angina (3,4). Recent studies with chimeric 7E3 Fab
(antibody directed against a b3integrin [aIIbb3, glycoprotein
IIb/IIIa]) have shown very encouraging clinical results early
and late after both high- and low-risk coronary angioplasty
(5,6).
Platelet adhesion and aggregation play significant roles in
acute coronary syndromes (7–9). Fibrinogen, fibronectin, vi-
tronectin, or von Willebrand Factor binding to platelet mem-
brane glycoprotein (GP) IIb/IIIa initiate platelet functional
responses (10,11). Thrombin-activated platelets adhere to leu-
kocytes via P-selectin (12–14). The interaction of platelets with
leukocytes involves P-selectin glycoprotein ligand-1 (PSGL-1)
and possibly CD11b/CD18 (Mac-1), which interacts with fi-
brinogen bound to platelets via GP IIb/IIIa or possibly tether-
ing on platelet ICAM-2 (15–17). Markers of thrombin gener-
ation and activity have been reported in patients undergoing
coronary angioplasty (17). The detection of activated platelets
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in clinical disorders, including unstable coronary syndromes or
coronary interventional procedures, has been described (18–
21). Several studies have found leukocyte and platelet activa-
tion under similar circumstances (22–28). The dynamics of
leukocyte–platelet interactions have been studied during car-
diac procedures (cardiopulmonary bypass or coronary angio-
plasty) or in patients with coronary artery disease (16,26,29–
32). Leukocyte activation or leukocyte-platelet complexes may
participate in the vascular inflammatory process, including
restenosis, following coronary angioplasty (25,32,33).
The CD11b/CD18 (Mac-1) is a heterodimer in the b2
integrin family (aMb2) that promotes adhesion of neutrophils
and monocytes to intercellular adhesion molecule 1 (ICAM-1)
on endothelial cells, extracellular matrix, iC3b and components
of the coagulation cascade (e.g., Factor X and fibrinogen). It is
stored in secretory granules in these leukocytes and can be
rapidly mobilized to the cell surface following cell activation.
Constitutive surface levels of CD11b are relatively low, with
approximately 50,000 binding sites per cell (34). Neutrophil
activation may increase surface levels of Mac-1 four- to
fivefold. Flow cytometric determination of leukocyte surface
levels of CD11b has been used as an index of activation of
these cells. The purpose of this study was to determine whether
peripheral blood leukocyte and platelet activation and inter-
action are affected by administration of chimeric 7E3 Fab
(ReoPro) during coronary angioplasty.
Methods
Patient population. The study group consisted of 50 pa-
tients undergoing elective coronary angioplasty. All of the
patients were stable at the time of angioplasty, having pre-
sented to the hospital with progressive angina, unstable angina
or recent acute myocardial infarction. All medications (aspirin,
heparin, nitrates, calcium channel or beta-blockers) were
continued throughout the hospitalization. Baseline blood stud-
ies obtained prior to the procedure included CBC, differential,
platelet count, PT/PTT, chemistry profiles, and lipoprotein
profile. This study was approved by the Institutional Review
Boards of Baylor College of Medicine and the Houston
Veterans Administration Medical Center, and all patients gave
written informed consent.
Angioplasty protocol. After local anesthesia (2% lidocaine,
20 cc), a 6F sheath was placed in the femoral vein and an 8F
sheath was placed in the femoral artery. The use of chimeric
7E3 Fab (ReoPro, Centocor, Leiden, The Netherlands) during
coronary angioplasty was based on the clinical judgment of the
individual operator and followed the manufacturer’s recom-
mendations (0.25 mg/kg intravenous bolus and 10 mg/min
infusion for 12 h), including heparin dose adjustments. After
discarding the initial 3-cc aspirate, blood was collected into
sterile plastic syringes from the venous sheath and placed in
vacutainers with 3.2% buffered citrate solution. The preproce-
dural sample was obtained before administration of heparin,
chimeric 7E3 Fab, or contrast material, and the postprocedural
sample was obtained after administration of all materials (35).
In six patients given chimeric 7E3 Fab, venous blood samples
were obtained 12 and 24 h after the procedure.
Monoclonal antibodies. With the exception of the anti-
CD18 monoclonal antibody (R15.7 provided by Dr. R. Roth-
lein, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Con-
necticut), the monoclonal antibodies were commercially
available, purified whole immunoglobulins. All studies in-
cluded isotype-specific irrelevant monoclonal antibodies with
the appropriate fluorescent label as controls (Becton Dickin-
son Immunocytometry Systems, San Jose, California). The
following antibodies were used for platelet studies: anti-CD41a
fluorescein isothiocyanate conjugated (FITC), which recog-
nizes IIb in the intact complex with IIIa of platelet GP IIb/IIIa
but not with IIb or IIIa separately (AMAC, Westbrook,
Maine); anti-CD61a fluorescein isothiocyanate conjugated
(FITC), which recognizes IIIa of platelet GP IIb/IIIa
(DAKOpatts, Denmark); and anti-CD62P phycoerythrin con-
jugated (PE), which recognizes the 140-kD single-chain GMP-
140 (P-selectin) of platelet membrane granule glycoprotein on
activated platelets (Serotec Ltd, Oxford, England). The follow-
ing antibodies were used for platelet–leukocyte studies: anti-
CD61a FITC or anti-CD41a FITC with either anti-CD45RO
phycoerythrin conjugated (PE), which recognizes a CD45
isoform present on neutrophils, monocytes, and lymphocytes
but neither erythrocytes nor platelets (DAKOpatts, Denmark),
or anti-CD14 phycoerythrin conjugated (PE), which recognizes
Mo2 present on monocytes (Becton Dickinson Immunocytom-
etry Systems, San Jose, California). Neutrophil CD11b expres-
sion was studied with two phycoerythrin-conjugated monoclo-
nal antibodies (Leu-15, Becton Dickinson Immunocytometry
Systems; 2LPM19c, DAKOpatts, Denmark).
Neutrophil studies. Venous blood samples were collected
from healthy adult individuals taking no medications to assess
the possible interaction of the chimeric 7E3 Fab with CD11b/
CD18 (Mac-1) on neutrophils. Each blood sample was divided
and anticoagulated with either heparin or citrate. Subsequent
comparisons showed no difference between the two anticoagu-
lants in individual neutrophil CD11b expression with the two
phycoerythrin-conjugated monoclonal antibodies studied
(Leu-15, Becton Dickinson Immunocytometry Systems;
2LPM19c, DAKOpatts, Denmark). Chimeric 7E3 Fab was
added to whole blood or isolated neutrophils at a final
concentration of 3.5 mg/ml and incubated at 37°C for 30 min
(optimal inhibitory concentration of neutrophil CD11b expres-
sion based upon studies ranging from 0.35 mg/ml to 350 mg/ml).
Isolated neutrophils were prepared from citrate anticoagu-
lated, dextran-sedimented venous blood over Ficoll-Hypaque
gradients and were suspended in Dulbecco’s phosphate-
buffered saline (PBS, Gibco, Grand Island, New York), pH 7.4,
containing 0.2% dextrose as previously described (36).
The isolation steps were carried out at room temperature,
and then neutrophils were maintained at room temperature in
PBS at a concentration of 107/ml. Isolated neutrophil prepa-
rations were confirmed to be free of platelet contamination
(anti-CD41a FITC) using flow cytometry (mean fluorescence
intensity similar to background and anti-IgG control) and
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direct visualization of fluorescent platelets attached to neutro-
phils (,1% neutrophils with any [#2] platelets). For in vitro
activation studies, neutrophils were stimulated with 10 nM
f-Met-Leu-Phe (fMLP). Isolated neutrophils were incubated
with chimeric 7E3 Fab (3.5 mg/ml) for 0, 5, 15, 30, 45 or 60 min
at 37°C prior to incubation with monoclonal antibody
(2LPM19c PE) for 30 min at 4°C. There was no change in
fluorescence intensity over this time course of incubation,
suggesting that chimeric 7E3 Fab did not cause internalization
or shedding of CD11b from the isolated neutrophils. There was
no difference in fluorescence intensity of isolated neutrophils
stained for CD11b expression (2LPM19c PE) when studies
were carried out at 4°C (15 or 30 min) with PBS compared to
chimeric 7E3 Fab.
Neutrophil adhesion assays. Round coverglasses (25 mm)
were coated with keyhole limpet hemocyanin (KLH; Sigma
Chemica, St. Louis, Missouri) and mounted in adhesion cham-
bers as previously described (37,38). Isolated neutrophils sus-
pended in PBS were allowed to settle onto this surface for
500 s, and then the chamber was inverted for an additional
500 s. The percentage of neutrophils remaining attached was
determined. Adhesion of isolated neutrophils without stimu-
lation was compared to fMLP-stimulated cells after incubation
(37°C for 15 min) with chimeric 7E3 Fab (3.5 mg/ml), anti-
CD18 (R15.7), or anti-IGg1 control.
Direct-labeled chimeric 7E3 Fab studies. To determine
whether there was direct binding of the chimeric 7E3 Fab to
neutrophils, either in whole blood or isolated preparations,
citrate anticoagulated venous blood samples were collected
from healthy adult individuals taking no medications. Chimeric
7E3 Fab (Lot 96D03AA, ReoPro, Centocor, Leiden, The
Netherlands) was conjugated with fluorescein isothiocyanate
using a commercially available kit (FITC Conjugation Kit,
Boehringer Mannheim Corp, Indianapolis, Indiana). Fluores-
cence saturation was determined by titration of the chimeric
7E3 Fab-labeled preparation with isolated platelets (5 3
107/ml) stimulated with ADP (20 mmol/liter). Live flow cyto-
metric analysis of whole blood or isolated neutrophil prepara-
tions was performed using intravital nuclear staining (LDS 751,
Molecular Probes, Eugene, Oregon) to allow triggering on
neutrophils. Chimeric 7E3 Fab FITC and Leu-15 PE binding
to neutrophils in whole blood or isolated preparations was
quantitated for both stimulated (10 nmol/liter fMLP) and
unstimulated neutrophils. The controls were anti-IGg1 FITC
and anti-IGg2a PE.
To determine whether there was direct binding of the
chimeric 7E3 Fab to monocytes, venous whole-blood samples
anticoagulated with EDTA were collected from healthy adult
individuals taking no medications. Next, 100 ml of anticoagu-
lated whole blood was incubated with saturating concentra-
tions of the antibody (chimeric 7E3 Fab FITC or anti-IGg1
FITC control). After a 20-min incubation in the dark at room
temperature, cells were washed (Tyrode’s-HEPES buffer),
resuspended in 1 ml of lysing reagent (Becton Dickinson
Immunocytometry Systems), mixed, incubated in the dark for
10 min at room temperature, and washed (TH-BSA). Cells
were resuspended in 200ml of 1% paraformaldehyde and
analyzed immediately. Measurement of monocyte FITC fluo-
rescence was done by live-gating on leukocyte-sized events,
using forward- versus side-scatter parameters to distinguish
monocytes.
Fluorescence labeling. For platelet or platelet–leukocyte
studies, the anticoagulated whole blood was immediately
placed in an equal volume of 2.5% paraformaldehyde at room
temperature for 5 min and then incubated at 4°C. After 1 h,
Tris-glycine solution, 1/8:v/v (250 mmol/liter Tris and 500
mmol/liter glycine) was added (to stop fixation). Samples were
kept refrigerated until the day’s study was completed (,3 h).
Samples were washed in Tyrode’s-HEPES buffer (HEPES 5
mmol/liter, NaCl 140 mmol/liter, KCl 2.7 mmol/liter, dextrose
5.5 mmol/liter, NaH2PO4 0.42 mmol/liter and NaHCO3 12
mmol/liter, pH 7.4) with 2 mg/ml of bovine serum albumin
(TH-BSA) and resuspended to the original volume. For leu-
kocyte and platelet activation studies, the anticoagulated
whole blood was refrigerated immediately without fixation.
For platelet studies, 5 ml of the fixed washed whole blood
was added to 40 ml of Tyrode’s-HEPES buffer and incubated
with saturating concentrations of one of the antibodies: anti-
CD41a FITC, anti-CD61a FITC, anti-CD62P PE, or anti-IGg1
(FITC and PE) controls. For platelet-activation studies, 5 ml of
anticoagulated unfixed whole blood was added to 35 ml of
Tyrode’s-HEPES buffer with 5 ml of either ADP (10 mmol/liter
final concentration) or thrombin receptor activating peptide
(7.5 mmol/liter final concentration [TRAP]) and incubated
with saturating concentrations of the antibodies as described
above; TRAP, the 11-amino acid (SFLLRNPNDKY-NH2)
thrombin receptor-activating peptide, was obtained from Pen-
insula Laboratories Europe Limited (Merseyside, England).
After a 20-min incubation in the dark at room temperature,
cells were resuspended in 2 ml of 1% paraformaldehyde and
stored in the dark at 4°C in 5 ml polystyrene snap cap tubes
until they could be read (,3 days). For leukocyte–platelet
studies, 100 ml of the fixed washed whole blood was incubated
with saturating concentrations of the antibodies: anti-CD61a
or anti-CD41a FITC and anti-CD45R0 PE, anti-IGg1 FITC
control and anti-CD45R0 PE, anti-CD61a or anti-CD41a
FITC and anti-CD14 PE, or anti-IGg1 FITC control and
anti-CD14 PE. For the neutrophil CD11b expression studies,
100 ml of anticoagulated unfixed whole blood or isolated
neutrophils was incubated with saturating concentrations of
the antibody (Leu 15 PE, 2LPM19c PE, or anti-IGg2a PE
control). After a 20-min incubation in the dark at room
temperature, cells were washed (Tyrode’s-HEPES buffer). The
whole blood or washed whole-blood samples were resus-
pended in 1 ml of lysing reagent (Becton Dickinson Immuno-
cytometry Systems), mixed, incubated in the dark for 10 min at
room temperature, and washed (TH-BSA). For leukocyte–
platelet studies or neutrophil studies, cells (from lyzed whole
blood or isolated preparations) were resuspended in 200 ml of
1% paraformaldehyde and stored in the dark at 4°C in 5 ml
polypropylene snap cap tubes until they could be read (,3
days).
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Flow cytometry. Samples were analyzed on a FACScan
flow cytometer (Becton Dickinson Immunocytometry Sys-
tems). Platelet surface CD41a, CD61a and CD62P (GP
IIb/IIIa and P-selectin, respectively) were measured by live
gating on platelet-sized events, using forward- versus side-
scatter parameters in log scale amplification to distinguish
platelets from erythrocytes. Three thousand platelet events
were collected and evaluated. For leukocyte–platelet stud-
ies, live gating was performed on leukocyte-sized events
(either neutrophils based on the anti-CD45R0 PE-labeled
population or monocytes based on the anti-CD14 PE-
labeled population). Assessment of 10,000 events for neu-
trophils and 5,000 events for monocytes was performed. The
percentage of leukocytes with positive platelet fluorescence
(FITC) and the mean platelet marker fluorescence intensity
of the leukocytes were recorded. Measurements of
leukocyte-surface CD11b was done by live gating on
leukocyte-sized events, using forward- versus side-scatter
parameters to distinguish neutrophils or monocytes. Ten
thousand events for neutrophils and 5,000 events for mono-
cytes were evaluated.
Statistical analysis. Data are presented as mean 6 SEM.
Comparisons between angioplasty study groups and sampling
times were made by analysis of variance. The Newman-Keuls
multiple comparison test was used to determine which means
were significantly different. Paired t test was used to compare
before and after angioplasty results for individual platients.
Time-dependent changes were determined by two-way re-
peated measures ANOVA. If the time factor main effect was
significant, a Newman-Keuls multiple comparison test was
used to determine which means were significantly different.
Contingency tables and chi-square with continuity correction
were used to compare study groups with respect to sex, race,
clinical circumstances, involved artery, risk factors, procedure
performed, and restenosis. A p # 0.05 was considered signif-
icant.
Results
Patient population. There were 50 patients studied (age
58 6 1 yr), 25 undergoing coronary angioplasty with and 25
without administration of chimeric 7E3 Fab (Table 1). Patients
selected to receive chimeric 7E3 Fab were younger. There
were no significant differences between the two treatment
groups with respect to sex or race. Racial composition of the
group included 12 blacks, 5 Hispanics and 33 whites. There was
no difference in age between the sexes or the racial groups.
White blood cell counts (8.8 6 0.5 3 103/mm3), differentials
(neutrophils 68 6 2%, lymphocytes 24 6 2%, monocytes 6 6
1%) and platelet counts (234 6 10 3 103/mm3) were within
normal ranges and not different between treatment groups.
Hypertension (78%), smoking (30%) and diabetes (36%) were
common in both groups. Chimeric 7E3 Fab tended to be
administered more often to patients with right coronary artery
procedures (Table 2). Heparin dose was expectedly lower with
administration of chimeric 7E3 Fab.
Leukocyte studies. Leukocyte CD11b expression was sim-
ilar in both study groups prior to the procedure. The CD11b
expression increased after angioplasty in control patients (neu-
trophils 171 6 25 to 255 6 31 mean fluorescence intensity
[MFI, mean 6 SEM], n 5 25, p , 0.0001; monocytes 200 6 40
to 248 6 36 MFI, n 5 17, p , 0.05) and decreased in the
patients selected to receive chimeric 7E3 Fab (neutrophils
146 6 30 to 82 6 22 MFI, n 5 25, p , 0.0001; monocytes 256 6
53 to 160 6 38 MFI, n 5 17, p , 0.05 [Fig. 1]). After the
procedure with chimeric 7E3 Fab, leukocyte CD11b expression
was lower than the control group.
Table 1. Baseline Patient Characteristics
Characteristic
Chimeric 7E3 Fab
(n 5 24)
Control
(n 5 25)
p
Value
Age (yr) 55.2 6 1.6 60.5 6 1.7 0.03
Male 72% 88% 0.11
White 60% 72% 0.08
Cholesterol (mg/dl) 196 6 12 199 6 7 0.95
Triglycerides (mg/dl) 171 6 16 166 6 16 0.91
LDL cholesterol (mg/dl) 125 6 14 135 6 7 0.49
HDL cholesterol (mg/dl) 35 6 3 32 6 2 0.42
Smoker 24% 36% 0.57
Hypertension 68% 88% 0.25
Diabetes 40% 32% 0.67
Ejection fraction 54 6 3% 57 6 2% 0.32
Prior CABG 16% 4% 0.28
Follow-up (months) 16.2 6 1.5 14.9 6 1.5 0.56
CABG 5 coronary artery bypass grafting; HDL 5 high density lipoprotein;
LDL 5 low density lipoprotein.
Table 2. Procedure Characteristics
Chimeric 7E3 Fab
(n 5 25)
Control
(n 5 25) p Value
Clinical circumstances 0.71
Elective 20% 20%
Recent MI 32% 20%
USA 48% 60%
Procedure 0.52
Balloon 32% 44%
Stent 52% 48%
Rotoblator 8% 0
Rotoblator with stent 8% 8%
Max atmospheres 13.3 6 1 13.7 6 1 0.74
No. of inflations 5.8 6 1 4.0 6 1 0.08
Balloon size 3.1 6 0.1 3.3 6 0.1 0.45
Heparin dose 9,100 6 500 12,200 6 700 0.0009
Coronary artery 0.06
LAD 36% 32%
RCA 44% 8%
LCX 16% 52%
LAD 1 LCX 0 4%
LCX1RCA 0 4%
SVG 4% 0
LAD 5 left anterior descending; LCX 5 left circumflex; Max 5 maximum;
MI 5 myocardial infarction; RCA 5 right coronary artery; SVG 5 saphenous
vein graft; USA 5 unstable angina.
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To assess further the possible interaction of the chimeric
7E3 Fab with CD11b/CD18 (Mac-1) on neutrophils, a number
of in vitro studies were performed using venous blood samples
from healthy adult individuals taking no medications. In fact,
when chimeric 7E3 Fab was incubated with the whole blood at
37°C, there was a significant decrease in neutrophil CD11b
detected in paired samples by flow cytometric techniques with
two different phycoerythrin-conjugated monoclonal antibodies
(p 5 0.01, Fig. 2). However, the expected increase in neutro-
phil CD11b expression after fMLP stimulation (10 nmol/liter)
was not prevented by incubation of chimeric 7E3 Fab with the
whole blood at 37°C (Fig. 2). This suggests that the chimeric
7E3 Fab may not be acting directly on the CD11b receptor.
Isolated neutrophils, free of platelet contamination, were
studied so as to define this interaction further. There was no
difference in the baseline or fMLP-stimulated CD11b expres-
sion on isolated neutrophil in vitro with or without chimeric
7E3 Fab (Fig. 3).
Adhesion of neutrophils is mediated by the b2integrins, in
particular CD11b/CD18. Under certain conditions, CD11a/
CD18 or CD11c/CD18 may be involved (39). Adhesion to
protein-coated surfaces is a reasonable surrogate used to
assess the CD11b functional properties and the impact of
specific monoclonal antibodies on them. Isolated neutrophils
from healthy adult individuals taking no medications (n 5 4)
were used for the adhesion assay. Adhesion of neutrophils in
Figure 1. Leukocyte CD11b expression. Peripheral blood samples
obtained pre- and postangioplasty were compared (paired t test). (a)
Neutrophil CD11b expression in the control group increased (n 5 25,
p , 0.0001), while neutrophil CD11b expression decreased in the
chimeric 7E3 group (n 5 25, p , 0.0001). Postprocedure, neutrophil
CD11b expression was lower in the chimeric 7E3 Fab group than the
control group (p , 0.0001). (b) Monocyte CD11b expression in the
control group increased (n 5 17, p , 0.05), while monocyte CD11b
expression decreased in the chimeric 7E3 group (n 5 17, p , 0.05).
Postprocedure, monocyte CD11b expression was lower in the chimeric
7E3 Fab group than in the control group (p , 0.05).
Figure 2. Neutrophil CD11b expression. Peripheral blood samples
obtained from healthy adult volunteers, incubated with 3.5 mg/ml
chimeric 7E3 Fab at 37°C for 30 min, showed a decrease in each
individual’s neutrophil CD11b expression (paired t test, n 5 5).
Peripheral whole blood samples obtained from healthy adult volun-
teers were incubated with 3.5 mg/ml chimeric 7E3 Fab at 37°C for
30 min and then stimulated with fMLP (10 nmol/liter) to determine if
this apparent decrease in detectable CD11b was of functional signifi-
cance. After stimulation, neutrophil CD11b expression increased
dramatically regardless of the presence of chimeric 7E3 Fab (paired t
test, n 5 5). Two phycoerythrin-conjugated monoclonal antibodies
were studied to confirm this finding (Leu-15, Becton Dickinson
Immunocytometry Systems, San Jose, California; 2LPM19c,
DAKOpatts, Denmark).
Figure 3. Isolated neutrophil CD11b expression. Neutrophils isolated
from peripheral blood of healthy adult volunteers were incubated with
3.5 mg/ml chimeric 7E3 Fab at 37°C for 30 min and then stimulated
with fMLP (10 nmol/liter). There was no difference in CD11b expres-
sion with or without chimeric 7E3, either before or after stimulation
with fMLP (paired t test, n 5 5). Two phycoerythrin-conjugated
monoclonal antibodies were studied to confirm this finding (Leu-15,
Becton Dickinson Immunocytometry Systems, San Jose, California;
2LPM19c, DAKOpatts, Denmark).
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the presence of a control monoclonal antibody was very low
(5.2 6 1.9%) and increased significantly after fMLP stimula-
tion (51.8 6 6.9%, p , 0.05). The adhesion of stimulated
neutrophils was prevented by anti-CD18 (7.3 6 3.0%), which
blocks all b2integrins, but not by chimeric 7E3 Fab (56.7 6
5.9%).
Finally, it seemed most important to determine whether a
difference existed between neutrophils in whole blood or in
isolated preparations with respect to possible binding of chi-
meric 7E3 Fab to the CD11b receptor. The FITC-labeled
chimeric 7E3 Fab was not detected bound to neutrophils using
live flow cytometric analysis of whole blood or isolated prep-
arations, with or without fMLP stimulation. Furthermore, the
FITC-labeled chimeric 7E3 Fab was not detected bound to
monocytes using live flow cytometric analysis of EDTA-
anticoagulated whole blood.
Platelet studies. Platelet activation increased after angio-
plasty in control patients (CD62P 8.9 6 0.8 to 12.3 6 1.2 MFI,
n 5 25, p , 0.05; CD41a 382 6 25 to 454 6 26 MFI, n 5 25,
p , 0.05, CD61a 436 6 52 to 529 6 58 MFI, n 5 11, p , 0.05)
and decreased in the patients selected to receive chimeric 7E3
Fab (CD62P 13.2 6 1.0 to 9.0 6 0.9 MFI, n 5 25, p , 0.05;
CD41a 365 6 29 to 36 6 7 MFI, n 5 25, p , 0.0001, CD61a
398 6 32 to 410 6 38 MFI, n 5 7, p 5 NS [Fig. 4]). Platelet
CD62P expression was higher before and lower after the
procedure in patients selected to receive chimeric 7E3 Fab
compared to the control group (p , 0.01). In both groups, in
vitro stimulation with TRAP or ADP, either before or after the
angioplasty, caused significant platelet activation, with an
increase in the three measured surface receptors (all p ,
0.0001, Table 3). Detection of in vitro-stimulated increase in
GP IIb/IIIa was limited when chimeric 7E3 Fab was adminis-
tered in vivo and anti-CD41a was used for detection (p ,
0.0001).
Time course of chimeric 7E3 Fab. To assess the duration of
the chimeric 7E3 Fab’s biologic influence on platelets and
leukocytes, six patients were studied at 12 h (the end of the
infusion) and 24 h. These patients were clinically stable and
asymptomatic during this time period. The decrease in leuko-
cyte CD11b expression persisted, as did the decline in platelet
activation (Table 4). The GP IIb/IIIa receptor remained
inaccessible to the anti-CD41a throughout this period.
Leukocyte–platelet interactions. Cytometric histograms
showed three peaks (arbitrarily called low, high, and very high)
of platelet fluorescence intensity on both monocytes and
neutrophils (32). The percent of neutrophils with more adher-
ent platelets tended to be higher in the control group both
before and after the procedure (Table 5). Both the mean
platelet fluorescence intensity of the leukocytes (i.e., the
number of platelets per leukocyte) and the percentage of
leukocytes with positive platelet fluorescence fell to near zero
after chimeric 7E3 Fab because it blocked access of the
antibody used to detect the platelets (GP IIb/IIIa receptor
[anti-CD41a]). When anti-CD61a was used to detect the
platelets, the increase in leukocytes with more adherent plate-
lets after the procedure still occurred in the control group but
not with chimeric 7E3 Fab present.
Subsequent studies. Nineteen patients (7 chimeric 7E3
Fab and 12 control, p 5 0.11) returned to the hospital with
chest pain and underwent repeat cardiac catheterization at a
median follow-up time of 16 months (range 3 to 26 months).
Findings in these cases were as follows: 7 had mild restenosis
(,50%) with progression of disease elsewhere and were
treated medically; 4 had significant restenosis and underwent
repeat angioplasty; 5 had significant new stenosis and under-
went angioplasty; and 3 were referred for coronary artery
bypass grafting because of significant restenosis and progres-
sion of disease elsewhere. The incidence of significant resten-
osis was lower in the chimeric 7E3 group (1 chimeric 7E3 Fab
and 6 control, p , 0.01). There was one death (2%) during this
time. This patient had diabetes and an ischemic cardiomyop-
athy (EF 25%). He developed restenosis 9 weeks after chi-
meric 7E3 Fab infusion during rotoblator and stent placement
in an ostial saphenous vein graft to the obtuse marginal artery.
During the cardiac catheterization defining the restenosis, the
Figure 4. Platelet studies. Peripheral blood samples obtained pre- and
postangioplasty were compared (paired t test). (a) Platelet P-selectin
(CD62) expression in the control group increased (n 5 25, p , 0.05),
while platelet P-selectin (CD62) expression decreased in the chimeric
7E3 group (n 5 25, p , 0.05). Preprocedure platelet P-selectin (CD62)
expression was higher and postprocedure platelet P-selectin (CD62)
expression was lower in the chimeric 7E3 Fab group than the control
group (p , 0.01). (b) Platelet GP IIb/IIIa expression (as detected by
anti-CD41a) in the control group increased (n 5 25, p , 0.05), while
the GP IIb/IIIa receptor was not accessible to the anti-CD41a in the
chimeric 7E3 group (n 5 25, p , 0.0001).
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patient developed ventricular fibrillation and could not be
resuscitated.
Discussion
The long-term success of coronary angioplasty has been
limited by restenosis (40). Various pharmacologic strategies
have not eliminated this problem (41). One promising phar-
macologic therapy for the reduction in clinical restenosis has
been the use of chimeric 7E3 Fab (5,6). Although the most
obvious mechanism by which this drug reduces the incidence of
restenosis involves platelet inhibition, the biologic impact may
be much greater owing to cross specificity with other integrins.
Aspects of the restenotic process that could be influenced
include inflammatory cells, vascular endothelium, smooth mus-
cle cell proliferation, and the coagulation cascade (42–44).
Leukocyte studies. Results from this study suggest, as other
investigators have found, that leukocyte activation (i.e., in-
creased CD11b expression) can be detected in peripheral
blood after routine coronary angioplasty when chimeric 7E3
Fab is not used (23–25,27,28). It is unlikely that the activation
state would diminish during angioplasty. However, when chi-
meric 7E3 Fab was administered, leukocyte CD11b expression,
especially on neutrophils, diminished and remained low for
some time. A prolonged interaction of the chimeric 7E3 Fab
with platelets from normal subjects has already been reported
(45).
This diminution in CD11b expression on neutrophils occurs
in vivo or in vitro when whole blood is incubated at body
temperature with the chimeric 7E3 Fab. The CD11b expres-
sion of isolated neutrophils incubated at 37°C with chimeric
7E3 Fab did not diminish. No change occurred in CD11b
expression on isolated neutrophils over time, suggesting that
chimeric 7E3 Fab did not cause internalization or shedding of
CD11b from the isolated neutrophils. The 3.5 mg/ml concen-
tration used (based on in vitro titration of the effect of chimeric
7E3 Fab on neutrophil CD11b expression in whole blood from
healthy adult individuals taking no medications) was similar to
the 2.4 6 0.4 mg/ml detected 5 min after the standard bolus
dose in patient undergoing elective coronary angioplasty (46).
Changes in CD11b expression, either on isolated neutro-
phils or neutrophils or monocytes in whole blood, did not
appear to involve direct interactions of the FITC-labeled
chimeric 7E3 Fab with the receptor. This is in contrast to in
vitro studies, in which the whole murine monoclonal antibody
(7E3) appeared to attach to CD11b of ADP-stimulated periph-
Table 3. Ex vivo Platelet Stimulation Studies*
Unstimulated* TRAP (7.5 mmol/liter) ADP (10 mmol/liter)
P-selectin expression
Control group (n 5 25)
Before angioplasty 8.9 6 0.8 196 6 23 126 6 23
After angioplasty 12.3 6 1.2† 185 6 25 110 6 21
Chimeric 7E3 Fab group (n 5 25)
Before angioplasty 13.2 6 1.0 214 6 36 150 6 66
After angioplasty 9.0 6 0.9‡ 210 6 43 162 6 49
GP IIb/IIIa expression
(detected with CD41a)
Control group (n 5 25)
Before angioplasty 382 6 25 757 6 30 739 6 28
After angioplasty 454 6 26† 830 6 59 703 6 55
Chimeric 7E3 Fab group (n 5 25)
Before angioplasty 365 6 29 737 6 43 614 6 31
After angioplasty 36 6 7§ 266 6 28§ 188 6 37§
GP IIb/IIIa expression
(detected with CD61a)
Control group (n 5 11)
Before angioplasty 436 6 52 640 6 23 671 6 47
After angioplasty 529 6 58† 706 6 38 733 6 35
Chimeric 7E3 Fab group (n 5 7)
Before angioplasty 398 6 32 690 6 31 656 6 37
After angioplasty 410 6 38 667 6 21 642 6 35
*Flow cytometric studies with results reported as mean fluorescence intensity. *p , 0.0001 unstimulated , TRAP or
ADP stimulated. †p , 0.05 before , after angioplasty. ‡p , 0.05 before . after angioplasty. §p , 0.0001 before . after
angioplasty. TRAP 5 thrombin receptor-activating peptide; ADP 5 adenosine diphosphate.
Table 4. Time Course of Chimeric 7E3 Fab Effect on Detectable
Platelet and Leukocyte Receptors
CD11b*
Neutrophils
CD11b*
Monocytes CD41a* CD62P*
Before angioplasty 190 6 20 270 6 22 455 6 49 15.2 6 1.2
After angioplasty 122 6 12 165 6 33 32 6 7 10.7 6 1.4
12 h after angioplasty 54 6 10 156 6 28 47 6 15 9.8 6 0.8
24 h after angioplasty 91 6 13 243 6 55 103 6 19 11.0 6 1.6
*p , 0.0001 change over time, n 5 6.
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eral blood monocytes or a cultured monocytic cell line (47).
Monocytes have a much higher affinity for platelet binding
than do neutrophils (14,29). Thus, the possibility that these
monocytes were contaminated with platelets, which are clearly
activated by ADP and would themselves bind the antibody,
must be excluded. Our attempts to isolate monocytes that were
not activated or contaminated with platelets were not success-
ful. Thus, we can only report on the monocytes and neutrophils
in whole blood, or neutrophils that were isolated with minimal
activation or platelet contamination.
A recent investigation reported by Simon et al. (48), studied
the interaction of the 7E3 antibody and monocytic cells (two
different cell lines [erythroleukemic K562 cells and CHO cells]
transfected with the aM subunit of Mac-1 [CD11b]). The 7E3
antibody was detected bound directly to the K562 cells using
flow cytometric techniques. Both the 7E3 and chimeric 7E3
Fab blocked two Mac-1 (CD11b)-dependent adhesive proper-
ties (adhesion to fibrinogen of a monocytic cell line [THP-1
cells] and adhesion to ICAM-1 of transfected CHO cells). Our
inability to document antibody binding to monocytes or neu-
trophils may be related to differences in the two antibodies
(whole murine vs. chimeric Fab) or differences in the cell types
(neutrophils vs. monocytes versus transfected cell lines) with
respect to Mac-1 (CD11b) binding. Although we did not find
any functional changes in isolated neutrophils (ex vivo adhe-
sion assay) or fMLP responsiveness of either isolated neutro-
phils or neutrophils in whole blood induced by chimeric 7E3
Fab, this does not exclude an effect on neutrophil functional
responses in vivo.
Platelet studies. Changes in platelet P-selectin (CD62P)
were small but directional; thus, paired analysis showed signif-
icant difference between the patient groups: increases after
routine angioplasty and decreases when chimeric 7E3 Fab was
used. Several investigators have found platelet P-selectin to be
increased after coronary angioplasty (49,50). After routine
balloon angioplasty for stable angina, Serrano et al. (28) found
evidence of increased platelet GP IIb/IIIa expression, which is
another marker of platelet activation (51). In our study,
increases in the platelet GP IIb/IIIa receptor density was
documented with two different monoclonal antibodies (anti-
Table 5. Leukocyte–Platelet Interactions*
Low High Very High
Neutrophils
(platelets detected with CD41a)
Before angioplasty
Control (n 5 25) 5 6 1 (50 6 6%) 34 6 6 (26 6 5%) 256 6 50 (24 6 5%)
Chimeric 7E3 Fab (n 5 25) 6 6 1 (58 6 5%) 44 6 6 (32 6 4%) 375 6 82 (10 6 4%)
After angioplasty
Control (n 5 25) 5 6 1 (41 6 6%) 52 6 7 (26 6 4%) 380 6 57 (34 6 5%)‡
Chimeric 7E3 Fab (n 5 25) 6 6 1 (93 6 3%)† 11 6 3a (7 6 2%)† 0†
(platelets detected with CD61a)
Before angioplasty
Control (n 5 11) 8 6 1 (43 6 10%) 78 6 13 (36 6 9%) 796 6 103 (20 6 4)
Chimeric 7E3 Fab (n 5 7) 6 6 1 (44 6 8%) 95 6 24 (48 6 5%)i 642 6 116 (8 6 2)§
After angioplasty
Control (n 5 11) 9 6 2 (32 6 7%) 77 6 10 (41 6 5%) 1139 6 150‡ (27 6 10)
Chimeric 7E3 Fab (n 5 7) 5 6 1 (47 6 6%)¶ 90 6 21 (46 6 5%) 667 6 120§ (7 6 2%)§
Monocytes
(platelets detected with CD41a)
Before angioplasty
Control (n 5 17) 5 6 1 (50 6 3%) 38 6 4 (30 6 4%) 356 6 39 (20 6 5%)
Chimeric 7E3 Fab (n 5 17) 6 6 1 (50 6 7%) 60 6 6¶ (35 6 6%) 402 6 89 (15 6 4%)
After angioplasty
Control (n 5 17) 5 6 1 (32 6 6%)i 42 6 5 (31 6 4%) 418 6 67 (37 6 6%)‡
Chimeric 7E3 Fab (n 5 17) 7 6 1 (84 6 5%)† 18 6 3† (16 6 5%)† 0†
(platelets detected with CD61a)
Before angioplasty
Control (n 5 11) 5 6 1 (40 6 4%) 50 6 3 (34 6 5%) 460 6 46 (26 6 5%)
Chimeric 7E3 Fab (n 5 7) 5 6 1 (26 6 7%)§ 55 6 3 (46 6 7%)¶ 325 6 63 (28 6 9%)
After angioplasty
Control (n 5 11) 6 6 2 (20 6 7%)i 52 6 8 (42 6 6%)‡ 890 6 198b (38 6 9%)‡
Chimeric 7E3 Fab (n 5 7) 5 6 1 (29 6 9%) 58 6 7 (49 6 6%) 285 6 73c (22 6 5%)§
*Cytometric histograms showed three peaks of platelet fluorescence intensity on monocytes and neutrophils
arbitrarily called low, high, and very high. Results reported as mean fluorescence intensity with the (%) of cells in that
intensity range. †p , 0.0001 different from baseline 7E3 and either control time point. ‡p , 0.05 before , after
angioplasty for treatment group. §p , 0.05 7E3 , control. ip , 0.05 before . after angioplasty for treatment group. ¶p ,
0.05 7E3 . control.
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CD41a recognizes IIb in the intact complex with IIIa of
platelet GP IIb/IIIa but not with IIb or IIIa separately;
anti-CD61a recognizes IIIa of platelet GP IIb/IIIa). After
chimeric 7E3 Fab and the angioplasty procedure, surface
expression of platelet P-selectin declined and platelet GP
IIb/IIIa did not increase (as detected by anti-CD61a). Chi-
meric 7E3 Fab does not react directly with platelet surface
P-selectin or the site of anti-CD61a binding; however, in vivo it
may ameliorate some of the platelets’ responsiveness to ago-
nists that do increase either receptor’s surface expression.
While unlikely, perhaps more activated platelets were removed
from the peripheral circulation or more surface P-selectin was
lost when chimeric 7E3 was used and thus the lower level of
platelet P-selectin.
In both groups, in vitro platelet stimulation with TRAP or
ADP, either before or after the angioplasty, caused a signifi-
cant increase in platelet P-selectin. This finding suggests that in
vitro the chimeric 7E3 Fab had no direct effect on the internal
pool of P-selectin or its mobilization to the cell surface.
Platelet GP IIb/IIIa, as detected by anti-CD41a, was effectively
blocked for 24 h by the bolus followed by 12-h infusion of
chimeric 7E3 Fab, which has been described (45). Kleiman et
al. (46) found inhibition of ex vivo platelet aggregation (TRAP,
ADP, collagen) early after only the bolus of chimeric 7E3 Fab,
but aggregation returned to 70% of baseline by 24 h. The
concentration of chimeric 7E3 Fab present in the whole blood
from our patients, which was diluted 1:10 for the platelet flow
cytometry studies, was adequate to block detection (anti-
CD41a) of many of the newly externalized GP IIb/IIIa recep-
tors stimulated with TRAP or ADP. The flow cytometric
detection (anti-CD61a) of newly externalized GP IIb/IIIa
receptors, after stimulation with TRAP or ADP, was similar in
both treatment groups. Thus, the chimeric 7E3 Fab did not
prevent platelet activation in vitro with these two agonists.
Leukocyte–platelet interactions. Involvement of leuko-
cytes in coronary atherosclerosis and thrombosis has been
demonstrated in several recent clinicopathologic studies
(44,52). Adhesion molecules of the immunoglobulin superfam-
ily, intercellular adhesion molecule-1 (ICAM-1 [CD54]) and
vascular cell adhesion molecule-1 (VCAM-1 [CD106]), are
expressed by intimal neovasculature of atherosclerotic plaques
and associated with an increased intimal leukocyte accumula-
tion probably via CD11b (Mac-1). Platelets and locally derived
thrombin have been associated with acute coronary syndromes,
nonocclusive thrombus formation during angioplasty, and re-
stenosis. Patients with active coronary artery disease have
enhanced in vivo adhesive interactions between platelets and
leukocytes (14,26,32,53). The complexes may modulate the
proinflammatory and prothrombotic effects of neutrophils and
monocytes. In this study, patients selected to receive chimeric
7E3 Fab had evidence of fewer leukocyte–platelet complexes
than did the control group after the angioplasty. This is not
surprising as both leukocyte CD11b and platelet P-selectin
expression also diminished, suggesting that passivation of both
cell types may have occurred.
Study limitations. The most serious limitation of this study
is the small number of patients studied in a nonrandomized
fashion. Another major limitation is the incompleteness of
some data. Seventeen patients in each treatment group had an
adequate number of monocytes in the peripheral blood to
obtain good flow cytometric data. Studies with two GP IIb/IIIa
antibodies were not obtained on all patients, but enough
studies were performed to allow analysis of the data. A third
issue involves the technical aspects of flow cytometric analysis
of peripheral blood. It is virtually certain that what is happen-
ing in the coronary artery at and distal to the lesion is different
from what we are able to study in the peripheral blood.
Technically sampling blood at the site of angioplasty and distal
to it is difficult and would add delays and possibly risks to the
procedure. Sampling from the coronary vein, after the blood
has passed through the capillary bed and venous circulation,
may not be much different from peripheral blood, and again
this would add delays and possibly risks to the procedure.
Variations occur, and comparing absolute fluorescence inten-
sities, as we have done, is problematic. However, each antibody
was consistently obtained from a single manufacturer and
carefully titrated. There was little change in absolute fluores-
cence intensity of CD11b, CD41a, CD61a and CD62P expres-
sion of the control subjects routinely used for clinical determi-
nations during this time.
Conclusions. Despite standard aspirin and heparin ther-
apy, leukocyte and platelet activation with platelet adherence
to leukocytes occurs after coronary angioplasty. Although
chimeric 7E3 Fab does not bind to leukocytes directly, it
influences CD11b expression on leukocytes in whole blood. In
this small nonrandomized study, the incidence of significant
restenosis was lower in the chimeric 7E3 group. Thus, modu-
lation of platelet and leukocyte activation and interaction by
chimeric 7E3 Fab may contribute to an improved outcome
after coronary angioplasty.
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